Reviva Historical Income Statement

RVPHW Stock

USD 0.22 0.01 4.35%

Historical analysis of Reviva Pharmaceuticals income statement accounts such as Interest Expense of 156.3 K, Selling General Administrative of 8.5 T, Total Revenue of 0.0 or Other Operating Expenses of 41.5 M can show how well Reviva Pharmaceuticals Holdings performed in making a profits. Evaluating Reviva Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Reviva Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Reviva Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Reviva Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

About Reviva Income Statement Analysis

Reviva Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Reviva Pharmaceuticals shareholders. The income statement also shows Reviva investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Reviva Pharmaceuticals Income Statement Chart

At this time, Reviva Pharmaceuticals' Net Interest Income is fairly stable compared to the past year. Interest Income is likely to climb to about 523.9 K in 2024, whereas Depreciation And Amortization is likely to drop slightly above 212.7 K in 2024.

Tax Provision Selling General Administrative Other Operating Expenses Research Development

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Reviva Pharmaceuticals. It is also known as Reviva Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Reviva Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Reviva Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

	2021	2023	2024 (projected)
Depreciation And Amortization	1.6M	223.9K	212.7K
Interest Income	182.8K	499.0K	523.9K

Depreciation And Amortization Interest Income

Reviva Pharmaceuticals income statement Correlations

	Tax Provision	Net Interest Income	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Cost Of Revenue
Tax Provision		0.77	0.75	0.26	-0.5	0.57	0.85	-0.58	-0.87	-0.96	0.57	-0.58	0.57	-0.88	-0.87	0.57	-0.58	-0.58	0.61	-0.47
Net Interest Income	0.77		0.77	0.33	-0.87	0.73	0.84	-0.73	-0.83	-0.82	0.73	-0.73	0.73	-0.81	-0.83	0.73	-0.73	-0.73	0.69	-0.69
Interest Income	0.75	0.77		0.32	-0.39	0.93	0.97	-0.93	-0.97	-0.88	0.93	-0.93	0.93	-0.87	-0.97	0.93	-0.93	-0.93	0.88	-0.88
Depreciation And Amortization	0.26	0.33	0.32		-0.42	0.06	0.24	-0.06	-0.21	-0.34	0.06	-0.06	0.06	-0.61	-0.21	0.06	-0.06	-0.06	0.06	-0.06
Interest Expense	-0.5	-0.87	-0.39	-0.42		-0.36	-0.47	0.36	0.45	0.5	-0.36	0.36	-0.36	0.57	0.45	-0.36	0.36	0.36	-0.34	0.34
Selling General Administrative	0.57	0.73	0.93	0.06	-0.36		0.9	-1.0	-0.89	-0.71	1.0	-1.0	1.0	-0.66	-0.89	1.0	-1.0	-1.0	0.95	-0.95
Other Operating Expenses	0.85	0.84	0.97	0.24	-0.47	0.9		-0.9	-1.0	-0.94	0.9	-0.9	0.9	-0.89	-1.0	0.9	-0.9	-0.9	0.85	-0.85
Operating Income	-0.58	-0.73	-0.93	-0.06	0.36	-1.0	-0.9		0.89	0.71	-1.0	1.0	-1.0	0.66	0.89	-1.0	1.0	1.0	-0.96	0.93
Net Income From Continuing Ops	-0.87	-0.83	-0.97	-0.21	0.45	-0.89	-1.0	0.89		0.95	-0.89	0.89	-0.89	0.88	1.0	-0.89	0.89	0.89	-0.86	0.83
Ebit	-0.96	-0.82	-0.88	-0.34	0.5	-0.71	-0.94	0.71	0.95		-0.71	0.71	-0.71	0.95	0.95	-0.71	0.71	0.71	-0.68	0.66
Research Development	0.57	0.73	0.93	0.06	-0.36	1.0	0.9	-1.0	-0.89	-0.71		-1.0	1.0	-0.66	-0.89	1.0	-1.0	-1.0	0.95	-0.95
Ebitda	-0.58	-0.73	-0.93	-0.06	0.36	-1.0	-0.9	1.0	0.89	0.71	-1.0		-1.0	0.66	0.89	-1.0	1.0	1.0	-0.96	0.93
Total Operating Expenses	0.57	0.73	0.93	0.06	-0.36	1.0	0.9	-1.0	-0.89	-0.71	1.0	-1.0		-0.66	-0.89	1.0	-1.0	-1.0	0.95	-0.95
Reconciled Depreciation	-0.88	-0.81	-0.87	-0.61	0.57	-0.66	-0.89	0.66	0.88	0.95	-0.66	0.66	-0.66		0.88	-0.66	0.66	0.66	-0.63	0.62
Income Before Tax	-0.87	-0.83	-0.97	-0.21	0.45	-0.89	-1.0	0.89	1.0	0.95	-0.89	0.89	-0.89	0.88		-0.89	0.89	0.89	-0.86	0.83
Total Other Income Expense Net	0.57	0.73	0.93	0.06	-0.36	1.0	0.9	-1.0	-0.89	-0.71	1.0	-1.0	1.0	-0.66	-0.89		-1.0	-1.0	0.95	-0.95
Net Income	-0.58	-0.73	-0.93	-0.06	0.36	-1.0	-0.9	1.0	0.89	0.71	-1.0	1.0	-1.0	0.66	0.89	-1.0		1.0	-0.96	0.93
Income Tax Expense	-0.58	-0.73	-0.93	-0.06	0.36	-1.0	-0.9	1.0	0.89	0.71	-1.0	1.0	-1.0	0.66	0.89	-1.0	1.0		-0.96	0.93
Gross Profit	0.61	0.69	0.88	0.06	-0.34	0.95	0.85	-0.96	-0.86	-0.68	0.95	-0.96	0.95	-0.63	-0.86	0.95	-0.96	-0.96		-0.8
Cost Of Revenue	-0.47	-0.69	-0.88	-0.06	0.34	-0.95	-0.85	0.93	0.83	0.66	-0.95	0.93	-0.95	0.62	0.83	-0.95	0.93	0.93	-0.8

Click cells to compare fundamentals

Reviva Pharmaceuticals Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Reviva Stock Analysis

When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Reviva Historical Income Statement

About Reviva Income Statement Analysis

Reviva Pharmaceuticals Income Statement Chart

Tax Provision

Other Operating Expenses

Reviva Pharmaceuticals income statement Correlations

Reviva Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Reviva Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Research Development	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Total Other Income Expense Net	+ 1.0	Selling General Administrative
Ebitda	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Income Tax Expense	+ 1.0	Operating Income

Income Tax Expense	- 1.0	Total Other Income Expense Net
Net Income	- 1.0	Total Other Income Expense Net
Income Tax Expense	- 1.0	Total Operating Expenses
Net Income	- 1.0	Total Operating Expenses
Total Other Income Expense Net	- 1.0	Ebitda
Total Operating Expenses	- 1.0	Ebitda